Lexaria Bioscience Corp Stock Price, News & Analysis

Lexaria Bioscience Corp. announced the licensing of its DehydraTECH technology to Valcon Medical A/S, a European contract manufacturing organization. This license targets medical cannabis applications in the EU and UK. Lexaria is set to receive milestone fees and royalties from product sales, optimizing revenue potential as Valcon manufactures various cannabis products. Valcon's GMP certification enhances their credibility in the market. This collaboration aims to capitalize on the growing demand for effective medical cannabis solutions.

Lexaria Bioscience Corp. held its 2022 Annual Meeting on May 31, with 49.2% of shares represented. Key voting results included:

• Chris Bunka elected with 97.15% approval
• John Docherty elected with 87.25% approval
• Nicholas Baxter elected with 84.5% approval
• Ted McKechnie elected with 96.1% approval
• Albert Reese Jr. elected with 96.56% approval
• Davidson & Company LLP appointed as auditors with 98.77% approval
• Non-binding compensation approval for executives at 93.52%
• Directors' past actions ratified at 91.1%

Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced the availability of a new broadcast titled, “Nicotine Surges as Smoking Sags.” The global smoking cessation market is projected to grow significantly, with nicotine pouch sales expected to rise from $2.33 billion in 2020 to $21.84 billion by 2027. Lexaria's DehydraTECH technology enhances drug absorption, evidenced by its ability to boost cannabinoid and nicotine bioabsorption significantly. With 25 patents granted and 50 pending, Lexaria aims to expand applications of its technology for various pharmaceuticals.

Lexaria Bioscience Corp. (NASDAQ: LEXX) has been featured in an editorial by NetworkNewsWire, highlighting its innovation in the nicotine market. The company’s patented DehydraTECH delivery platform enhances oral delivery of nicotine and pharmaceuticals, promising bioabsorption increases of up to ten times. The global nicotine market reached approximately $853 billion in 2020, showcasing significant growth potential. Lexaria holds 25 granted patents and over 50 pending worldwide, further establishing its position in a competitive industry.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the receipt of its 25th patent for its DehydraTECH technology, specifically aimed at enhancing the delivery of antiviral drugs. The patent, No. 11,311,559, will be issued on April 26, 2022, validating the effectiveness of DehydraTECH in improving bioavailability. Studies show that antiviral drugs processed with this technology achieve peak blood concentrations double that of standard drugs. This patent reinforces Lexaria's commitment to innovation in drug delivery and enhances its patent portfolio across various countries.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has initiated a multi-week human clinical study, HYPER-H21-4, aimed at evaluating the effectiveness of DehydraTECH-CBD for reducing blood pressure and other clinical benefits. This randomized, double-blind study involves 60 participants and is designed to bolster Lexaria's chances for an Investigational New Drug application with the FDA. Preliminary results show no serious adverse events, indicating good tolerance of DehydraTECH-CBD. The hypertension market, valued at $28 billion, presents a significant opportunity for Lexaria's innovative treatment.

Lexaria Bioscience Corp. announced positive results from its pulmonary hypertension clinical study, HYPER-H21-3, showing DehydraTECH-CBD significantly reduced pulmonary artery systolic pressure (PASP) in male participants. The treatment demonstrated a 41% overall reduction in PASP (p=0.045) during hypoxic conditions, supporting further research efforts. Lexaria intends to utilize these findings to seek FDA approval for formal clinical testing in hypertension management. The global hypertension market, valued at $28 billion, presents a significant opportunity for DehydraTECH-CBD as a potential treatment option.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a new human nicotine study, NIC-H22-1, set to commence this summer, involving a minimum of 36 participants. The double-blinded study aims to compare the performance of Lexaria's DehydraTECH-nicotine pouches against leading brands like ON! and Zyn, with a focus on pharmacokinetic data and subjective user experiences. Lexaria previously noted success in animal studies, showing a significant increase in nicotine absorption speed. The oral nicotine pouch market is projected to grow significantly, reaching $21.84 billion by 2027.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.